Although the rapid development of drug resistance is a known problem with targeted cancer therapies, recent studies have uncovered other surprises with RAF kinase inhibitors. These drugs can paradoxically activate downstream ERK signaling in some settings, with important implications for their clinical use.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells
Scientific Reports Open Access 25 May 2016
-
RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer
Oncogenesis Open Access 15 July 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Flaherty, K.T. et al. N. Engl. J. Med. 363, 809–819 (2010).
Johannessen, C.M. et al. Nature 468, 968–972 (2010).
Nazarian, R. et al. Nature 468, 973–977 (2010).
Villanueva, J. et al. Cancer Cell 18, 683–695 (2010).
Garnett, M.J., Rana, S., Paterson, H., Barford, D. & Marais, R. Mol. Cell 20, 963–969 (2005).
Hatzivassiliou, G. et al. Nature 464, 431–435 (2010).
Heidorn, S.J. et al. Cell 140, 209–221 (2010).
Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M. & Rosen, N. Nature 464, 427–430 (2010).
Robert, C., Arnault, J.P. & Mateus, C. Curr. Opin. Oncol. published online, 10.1097/CCO.0b013e3283436e8c (29 December 2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Downward, J. Targeting RAF: trials and tribulations. Nat Med 17, 286–288 (2011). https://doi.org/10.1038/nm0311-286
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0311-286
This article is cited by
-
Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours
Oncogene (2017)
-
Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells
Scientific Reports (2016)
-
Haarzellleukämie
Der Internist (2015)
-
RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer
Oncogenesis (2013)
-
Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis
Oncogene (2013)
